Myriad Genetics price target lowered to $11 from $13 at BofA

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $11 from $13 and keeps an Underperform rating on the shares after Myriad reported Q4 sales in line with the mid-January topline preannouncement and reiterated its FY25 guidance. The firm’s lower price target accounts for peer group multiple compression, the analyst tells investors.